This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

The Justice Department has been looking into allegations involving Epogen, Enbrel and Aranesp. Amgen's ($AMGN) long-brewing settlement with the U.S. Justice ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...

THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...

Finally, some much-needed good news for Amgen. Dispelling fears that its anemia drug is unsafe, Amgen has release new data from a Phase III trial of Aranesp showing no difference in risk of death ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

Amgen has dodged a potential Aranesp bullet. A new study dubbed "TREAT" showed that while the anemia drug didn't improve the heart health of patients with chronic kidney disease, it didn't hurt, ...